(Q40581267)

21 September 2017

1 reference

title

The value of C-reactive protein measurement in rheumatoid arthritis (English)

1 reference

21 September 2017

1 reference

Otterness IG

1

1 reference

21 September 2017

language of work or name

1 reference

1 October 1994

1 reference

Seminars in Arthritis and Rheumatism

21 September 2017

published in

1 reference

21 September 2017

volume

24

1 reference

21 September 2017

issue

2

1 reference

21 September 2017

page(s)

91-104

1 reference

SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

C-reactive protein: A critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

A membrane-bound form of the acute-phase protein C-reactive protein is the galactose-specific particle receptor on rat liver macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Characteristics of the binding of human C-reactive protein (CRP) to laminin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Localizing of C-reactive protein in synovium of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Extrahepatic transcription of human C-reactive protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Interleukin-6 and the acute phase response

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Does Drug Therapy Slow Radiographic Deterioration in Rheumatoid Arthritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Radiologic assessment as an outcome measure in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Quantification of keratan sulfate in blood as a marker of cartilage catabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Serum hyaluronan: a status report from the joint

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

C-reactive protein in rheumatology

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Erythrocyte sedimentation rate. From folklore to facts

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Relationship between plasma viscosity or ESR and the Ritchie articular index

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

C-reactive protein in the serial assessment of disease activity in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

C-reactive protein levels in patients with rheumatoid arthritis: the impact of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

C-reactive protein levels in systemic lupus erythematosus: a classification criterion?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Raised C-reactive protein response in rheumatoid arthritis patients with secondary Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

The relation of radiographic changes to serum acute-phase proteins and rheumatoid factor in 200 patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Circulating immune complexes and rheumatoid arthritis: a comparison of different assay methods and their early predictive value for disease activity and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Fall in immune complex levels during gold treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

The liver as the site of C-reactive protein formation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Progression of radiological changes in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Interleukin-6 in synovial fluid from patients with arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Elastolytic activity of human monocytes from synovial fluid and blood of patients with arthritis. Relations to levels of interleukin 6 and soluble interleukin 2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Interleukin-6 activity in paired samples of synovial fluid. Correlation of synovial fluid interleukin-6 levels with clinical and laboratory parameters of inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Anaemia of chronic disease in rheumatoid arthritis. Raised serum interleukin-6 (IL-6) levels and effects of IL-6 and anti-IL-6 on in vitro erythropoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Comparative studies of serum and synovial fluid C reactive protein concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Comparison of serum and synovial fluid concentrations of beta 2-microglobulin and C reactive protein in relation to clinical disease activity and synovial inflammation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

C reactive protein and immunoglobulin G in synovial fluid and serum in joint disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

The Leukocyte Protein L1 in Plasma and Synovial Fluid from Patients with Rheumatoid Arthritis and Osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Comparison and evaluation of a disease activity index for use in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

It is said that elevated erythrocyte sedimentation rate and the elevation of C-reactive protein (CRP) may be indicators of continuing joint destruction in rheumatoid arthritis. What then is the explanation for joint destruction in some patients in w

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Monitoring of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Can treatment really influence the radiological progression of rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Increased metacarpal bone mass following 18 months of slow-acting antirheumatic drugs for rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

The validity of surrogate markers in rheumatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Rheumatoid arthritis: C-reactive protein and erythrocyte sedimentation rate during initial treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

A human model screening system for the detection of specific antirheumatic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

A study of the influence of various antirheumatic drug regimens on serum acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Biochemical and clinical changes in rheumatoid arthritis: Their relation to the action of antirheumatoid drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

D-penicillamine withdrawal in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Report on chloroquine and dapsone in the treatment of rheumatoid arthritis: a 6-month comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis--a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Clinical and laboratory outcomes during the treatment of rheumatoid arthritis with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight–week randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Antirheumatic activity of fenclofenac

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

A comparison of platelet count and acute phase proteins in the measurement of disease activity in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Inhibition of interleukin 1 synthesis by tenidap: a new drug for arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Reduction of acute-phase proteins with tenidap sodium, a cytokine-modulating anti-rheumatic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Resin-coated 5-aminosalicylic acid (Asacol) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

A clinical and biochemical evaluation of etretinate in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Randomised, double blind, placebo controlled trial of inosine pranobex in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Phthalylsulphathiazole in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Treatment of early rheumatoid arthritis with rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Rifampicin in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Relationship between erythrocyte sedimentation rate and serum C-reactive protein in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Differential effects of therapeutic regimens on specific classes of rheumatoid factor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2805%2980003-4

7 January 2021

10.1016/S0049-0172(05)80003-4

Identifiers

DOI

1 reference

21 September 2017

1 reference